The US FDA has granted “orphan” status on BX004 from Israel’s BiomX (see here previously) for the treatment of chronic lung infections suffered by cystic fibrosis patients. Orphan designation is given for rare conditions that have no current treatment. https://ir.biomx.com/news-events/press-releases/detail/101/biomx-receives-orphan-drug-designation-from-the-u-s-food

Israel’s BiomX (see here previously) has reported positive initial results from its clinical trials of BX004. The treatment relieves chronic pulmonary infections in patients with cystic fibrosis. BiomX now plans to initiate a larger Phase 2/3 trial. https://ir.biomx.com/news-events/press-releases/detail/99/biomx-announces-positive-topline-results-from-part-2-of-the

I reported previously (see here) on BiomX. The Israeli biotech has now partnered with Janssen – the therapy R&D arm of Johnson & Johnson. BiomX’s XMarker microbiome-based platform will be used to classify responders to inflammatory bowel disease (IBD) therapies. … Continue reading →

I reported previously (28th May) on Israeli biotech BiomX which develops treatments using human bacteria (microbiome).  BiomX has now acquired Israel’s RondinX, which has built a cutting-edge technology platform set to unlock the potential of microbiome therapeutics. http://www.globes.co.il/en/article-biomx-buys-rondinx-in-israeli-microbiome-merger-1001216994

Israeli biotech BiomX is developing a pipeline of treatments for unmet medical needs, including cancer, inflammatory bowel disease and acne.  BiomX focuses on modulating the human microbiome – bacteria that reside in and on the human body – to boost … Continue reading →